The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Jupiter Wellness Acquisition Valuation
Is JWAC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of JWAC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate JWAC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate JWAC's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for JWAC?
Key metric: As JWAC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for JWAC. This is calculated by dividing JWAC's market cap by their current
earnings.
What is JWAC's PE Ratio?
PE Ratio
106.4x
Earnings
US$964.41k
Market Cap
US$102.58m
JWAC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Earnings vs Industry: JWAC is expensive based on its Price-To-Earnings Ratio (106.4x) compared to the US Capital Markets industry average (31.1x)
Price to Earnings Ratio vs Fair Ratio
What is JWAC's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
JWAC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
106.4x
Fair PE Ratio
n/a
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate JWAC's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.